Sensydia
Los Angeles, US · Founded 2015 · 14 employees on LinkedIn · 4 known investors
Sensydia develops the Cardiac Performance System (CPS), a non-invasive, automated platform that uses disposable sensors to measure advanced hemodynamic metrics such as ejection fraction, cardiac output, and pulmonary artery pressure. It is designed for use in hospitals (ICU, ER, bedside) and cardiology and medical offices to assess and manage heart failure, sepsis, trauma, and other critical cardiovascular conditions.
Founders & leadership
Board
GB
G. Bradford JonesBoard director
WK
VK
AM
Aman MahajanBoard director
TB
Thomas BruggereBoard director
Investors · 4
Colle Capital PartnersNew York · $500K – $2M
Frontier Venture CapitalBoulder · $50K – $500K
Orlando Health Venturesreported
Also in the syndicate · 1
Colle Capital
Reported raises · per SEC filings
Form D private placements$17.6M disclosed across 4 rounds · 2016–2023
▶$7.8MraisedMay 2023 · 23 investors · Other Health CareRule 506(b)
▶$7.8MraisedMay 2023 · 23 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Victoria GraceDirector
- Erick HawkinsDirector
- Anthony ArnoldExecutive Officer, Director
- William J. KaiserExecutive Officer
- Aman MahajanDirector
- Derrick SungDirector
- Offering amount
- $8.8M
- Amount sold
- $7.8M
- Minimum investment
- $1
- First sale
- May 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.1MraisedAug 2020 · 25 investors · OtherRule 506(b)
▶$4.1MraisedAug 2020 · 25 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Anthony ArnoldExecutive Officer, Director
- Aman MahajanExecutive Officer, Director
- Derrick SungDirector
- William J KaiserExecutive Officer
- Victoria K. GraceDirector
- Bradford G. JonesDirector
- Offering amount
- $4.1M
- Amount sold
- $4.1M
- Minimum investment
- $1
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$3.7MraisedAug 2017 · 11 investors · Other Health CareRule 506(b)
▶$3.7MraisedAug 2017 · 11 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Victoria K. GraceDirector
- G. Bradford JonesDirector
- Thomas BruggereExecutive Officer, Director
- Aman MahajanDirector
- William KaiserExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $3.7M
- Minimum investment
- $1
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$2MraisedAug 2016 · 13 investors · Other Health CareRule 506(b)
▶$2MraisedAug 2016 · 13 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- G. Bradford JonesDirector
- William KaiserExecutive Officer
- Thomas BruggereExecutive Officer, Director
- Victoria K. GraceDirector
- Aman MahajanExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $2M
- Minimum investment
- $1
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Medscape7 shared keywordsMedscape is an online medical information platform providing clinical news, expert perspectives, case studies, quizzes, and reference material across specialties such as cardiology, oncology, neurology, and psychiatry. It serves physicians, nurses, pharmacists, residents, and medical students.
Stimdia Medical6 shared keywordsStimdia Medical develops neuromodulation technologies, with a leadership team focused on clinical and regulatory affairs and R&D in critical care and pulmonary medicine. The company operates in the medical device sector.
Companies competing with Sensydia for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Sensydia do?
- Sensydia develops the Cardiac Performance System (CPS), a non-invasive, automated platform that uses disposable sensors to measure advanced hemodynamic metrics such as ejection fraction, cardiac output, and pulmonary artery pressure. It is designed for use in hospitals (ICU, ER, bedside) and cardiology and medical offices to assess and manage heart failure, sepsis, trauma, and other critical cardiovascular conditions.
- Who are Sensydia's investors?
- Sensydia's investors include Colle Capital Partners, Frontier Venture Capital, Orlando Health Ventures.
- How much funding has Sensydia raised?
- Sensydia has disclosed $17.6M raised across 4 rounds.
- Where is Sensydia headquartered?
- Sensydia is headquartered in Los Angeles, US.